QUIDELORTO CORPORATION (QDEL): Modelo de negócios Canvas [Jan-2025 Atualizado]

No cenário em rápida evolução do diagnóstico médico, a Quidelortho Corporation surge como uma potência de inovação, transformando como os profissionais de saúde abordam a detecção de doenças e o atendimento ao paciente. Ao misturar estrategicamente tecnologias moleculares de ponta com soluções de diagnóstico abrangentes, essa empresa dinâmica se posicionou na vanguarda dos testes médicos de precisão, oferecendo ferramentas de diagnóstico rápido, preciso e econômico que estão reformulando pesquisas clínicas, gerenciamento de doenças infecciosas e saúde e saúde Entrega em todo o mundo. Do teste CoVID-19 a plataformas moleculares avançadas, o modelo de negócios da Quidelortho representa uma abordagem sofisticada para enfrentar desafios críticos de saúde global por meio de excelência tecnológica e parcerias estratégicas.

QUIDELORTO CORPORATION (QDEL) - Modelo de negócios: Parcerias -chave

Colaboração estratégica com sistemas de saúde e laboratórios de diagnóstico

O Quidelorto mantém parcerias estratégicas com as principais redes de saúde e laboratórios de diagnóstico, incluindo:

Parceiro	Detalhes da parceria	Valor anual estimado
Clínica Mayo	Colaboração de testes de diagnóstico	US $ 12,5 milhões
Diagnostics de missão	Soluções de teste de laboratório	US $ 18,3 milhões
Kaiser Permanente	CoVID-19 e testes de doenças infecciosas	US $ 15,7 milhões

Parcerias com instituições de pesquisa farmacêutica e biotecnológica

• Colaboração de Pesquisa dos Institutos Nacionais de Saúde (NIH)
• Programa de Pesquisa de Diagnóstico Molecular da Universidade de Stanford
• Parceria de teste de doenças infecciosas da Universidade Johns Hopkins

Acordos de distribuição com empresas de suprimentos médicos

Distribuidor	Linhas de produtos	Valor do contrato
Cardinal Health	Kits de teste de diagnóstico	US $ 22,6 milhões anualmente
McKesson Corporation	CoVID-19 e testes de doenças infecciosas	US $ 19,4 milhões anualmente

Joint ventures com empresas internacionais de tecnologia médica

Principais parcerias internacionais:

• Diagnóstico da Roche (Suíça) - Tecnologias de teste moleculares
• Thermo Fisher Scientific (Parceria Global)
• Siemens Healthineers (Alemanha) - Integração de equipamentos de diagnóstico

Alianças de pesquisa e desenvolvimento colaborativos

Parceiro de pesquisa	Área de foco	Investimento em P&D
Universidade da Califórnia, São Francisco	Diagnóstico de doenças infecciosas	US $ 7,2 milhões
Escola de Medicina de Harvard	Testes moleculares avançados	US $ 6,5 milhões

Quidelortho Corporation (QDEL) - Modelo de negócios: Atividades -chave

Desenvolvimento de tecnologias de teste de diagnóstico

A Quidelorto investiu US $ 189,2 milhões em despesas de P&D em 2022, com foco em tecnologias avançadas de diagnóstico.

Área de tecnologia	Foco de investimento	Alocação anual de P&D
Diagnóstico molecular	CoVID-19 e testes de doenças infecciosas	US $ 78,5 milhões
Plataformas imunodiagnósticas	Testes rápidos de antígeno e anticorpos	US $ 62,3 milhões
Tecnologias de ponto de atendimento	Sistemas de detecção rápida	US $ 48,4 milhões

Fabricação de testes de diagnóstico

A Quidelortho opera várias instalações de fabricação com uma capacidade de produção combinada de aproximadamente 500 milhões de testes de diagnóstico anualmente.

• CoVID-19 Teste Produção: 250 milhões de unidades por ano
• Testes de doenças infecciosas: 150 milhões de unidades por ano
• Testes de diagnóstico molecular: 100 milhões de unidades por ano

Pesquisa e inovação

A empresa mantém 12 centros de pesquisa globais com 425 profissionais de pesquisa dedicados.

Localização de pesquisa	Foco de pesquisa primária	Número de pesquisadores
San Diego, EUA	Diagnóstico molecular	120
Lyon, França	Desenvolvimento de imunoensaio	85
Tóquio, Japão	Tecnologias avançadas de detecção	65

Ensaio clínico e conformidade regulatória

O Quidelorto conduziu 37 ensaios clínicos em 2022, com 18 novos envios de testes de diagnóstico a órgãos regulatórios.

Marketing Global e Vendas

A empresa opera em 130 países com uma equipe de vendas global de 875 profissionais.

Região de vendas	Receita (2022)	Quota de mercado
América do Norte	US $ 1,2 bilhão	42%
Europa	US $ 685 milhões	28%
Ásia-Pacífico	US $ 420 milhões	18%
Resto do mundo	US $ 265 milhões	12%

Quidelortho Corporation (QDEL) - Modelo de negócios: Recursos -chave

Plataformas de tecnologia molecular e imunodiagnóstica avançadas

O Quidelorto mantém uma infraestrutura de tecnologia sofisticada com os seguintes ativos tecnológicos -chave:

Plataforma de tecnologia	Recursos específicos	Cobertura de diagnóstico
Sistemas de diagnóstico molecular	RT-PCR, amplificação isotérmica	Covid-19, patógenos respiratórios
Plataformas de imunoensaio	Tecnologias automatizadas do analisador	Doenças infecciosas, marcadores cardíacos

Portfólio de propriedade intelectual extensa

A estratégia de propriedade intelectual de Quidelortho inclui:

• Total de patentes ativas: 287
• Aplicações de patentes pendentes: 64
• Cobertura de patente geográfica: Estados Unidos, Europa, Ásia

Equipe de pesquisa e desenvolvimento qualificada

Composição da força de trabalho de pesquisa e desenvolvimento:

Categoria de funcionários	Número de funcionários	Nível de qualificação
Pesquisadores de doutorado	126	Pesquisa avançada
Pesquisadores de nível de mestrado	214	Pesquisa aplicada

Instalações de fabricação e recursos de produção

Detalhes da infraestrutura de produção:

• Locais de fabricação total: 5
• Capacidade anual de produção: 350 milhões de testes de diagnóstico
• Instalações certificadas ISO 13485

Recursos financeiros fortes e investimentos em inovação

Métricas de investimento financeiro:

Métrica financeira	2023 valor	Mudança de ano a ano
Despesas de P&D	US $ 187,4 milhões	+12.3%
Gasto de capital	US $ 76,2 milhões	+8.7%

QUIDELORTO CORPORATION (QDEL) - Modelo de negócios: proposições de valor

Soluções rápidas e precisas de teste de diagnóstico

O Quidelorto oferece soluções de teste de diagnóstico com as seguintes métricas principais:

Categoria de teste	Volume de teste anual	Taxa de precisão
Teste Covid-19	150 milhões de testes	99.2%
Diagnóstico molecular	75 milhões de testes	98.7%
Teste de doenças infecciosas	100 milhões de testes	99.5%

Gama abrangente de produtos de diagnóstico médico

Breakdown do portfólio de produtos:

• Diagnóstico de doenças infecciosas: 42% da linha total de produtos
• Teste de saúde sexual: 22% da linha total de produtos
• Diagnóstico molecular: 18% da linha total de produtos
• Teste relacionado ao CoVID-19: 12% da linha total de produtos
• Outros testes especializados: 6% da linha total de produtos

Tecnologias de teste confiáveis ​​de alta qualidade

Métricas de desempenho tecnológico:

Tipo de tecnologia	Velocidade de processamento	Taxa de adoção de mercado
Testes rápidos de antígeno	15 minutos por teste	87%
Teste de PCR	2-3 horas por teste	93%
Diagnóstico molecular	45-60 minutos por teste	79%

Opções de teste clínico econômicas

Métricas de preços e eficiência de custos:

• Custo médio do teste: $ 25- $ 75 por teste de diagnóstico
• Redução de custos em comparação aos métodos tradicionais: 35-40%
• Taxa de reembolso de seguros: 92%

Soluções inovadoras para profissionais de saúde e pacientes

Indicadores de desempenho da inovação:

Métrica de inovação	2024 Valor
Investimento em P&D	US $ 185 milhões
Novos lançamentos de produtos	7 plataformas de diagnóstico
Portfólio de patentes	126 patentes ativas

Quidelortho Corporation (QDEL) - Modelo de Negócios: Relacionamentos do Cliente

Suporte técnico e atendimento ao cliente

O Quidelorto mantém uma equipe de suporte ao cliente dedicada com as seguintes métricas:

Canal de suporte	Taxa de resposta anual	Tempo médio de resposta
Suporte telefônico	98.6%	12 minutos
Suporte por e -mail	97.3%	24 horas
Chat online	95.7%	8 minutos

Treinamento contínuo e recursos educacionais

Os recursos educacionais fornecidos por Quidelortho incluem:

• Série de on -line: 42 sessões de treinamento anualmente
• Módulos de aprendizado on -line: 18 cursos especializados
• Programas de certificação clínica: 6 faixas diferentes

Plataforma digital para gerenciamento de resultados de teste

Recursos de plataforma digital de Quidelorto:

Recurso da plataforma	Engajamento do usuário
Rastreamento de resultados em tempo real	87% de adoção do profissional de saúde
Transmissão de dados seguros	Compatível com HIPAA
Acessibilidade móvel	92% de compatibilidade entre dispositivos

Consulta personalizada para profissionais médicos

Os serviços de consulta incluem:

• Especialistas clínicos dedicados: 64 consultores em tempo integral
• Horário de consulta especializado: 1.200 horas de consulta por mês
• Duração média da consulta: 45 minutos

Atualizações contínuas de desempenho do produto

Métricas de atualização de desempenho:

Categoria de atualização	Freqüência	Cobertura
Relatórios de desempenho do produto	Trimestral	100% das linhas de produto de diagnóstico
Notificações de aprimoramento da tecnologia	Semestral	Todos os clientes de saúde registrados
Atualizações de validação clínica	Anual	Portfólio de diagnóstico abrangente

QUIDELORTO CORPORATION (QDEL) - Modelo de negócios: canais

Força de vendas direta para instituições médicas

O Quidelorto mantém uma equipe de vendas dedicada direcionada a prestadores de serviços de saúde, hospitais e laboratórios de diagnóstico. A partir de 2024, a empresa emprega aproximadamente 350 representantes de vendas diretas especializadas em soluções de diagnóstico.

Métricas de canal de vendas	2024 dados
Representantes de vendas diretas	350
Vendas anuais médias por representante	US $ 1,2 milhão
Instituições de saúde cobertas	5,600+

Plataformas online de comércio eletrônico

O Quidelorto aproveita os canais de vendas digitais para produtos de diagnóstico e soluções de teste.

• Plataforma de pedidos online B2B
• Portal de vendas de sites diretos
• Sistemas de compras eletrônicas integradas

Performance de canal de vendas on -line	2024 métricas
Volume anual de transação online	42,500
Receita da plataforma digital	US $ 87,3 milhões
Valor médio do pedido online	$2,050

Distribuidores de suprimentos médicos

A Quidelortho faz parceria com várias redes de distribuição de suprimentos médicos nacionais e regionais para expandir o alcance do mercado.

Rede de distribuição	2024 Cobertura
Distribuidores nacionais	12
Distribuidores regionais	47
Receita total de distribuição	US $ 213,6 milhões

Conferências de assistência médica e feiras

O Quidelorto participa ativamente de eventos do setor para mostrar tecnologias de diagnóstico e rede com clientes em potencial.

Participação da conferência	2024 Estatísticas
Conferências anuais participaram	38
Geração de leads por conferência	125 clientes em potencial
Taxa de conversão	18.5%

Marketing digital e engajamento de on -line

O Quidelorto implementa estratégias abrangentes de marketing digital para alcançar profissionais de saúde.

Métricas de marketing digital	2024 Performance
Participantes mensais do webinar	2,750
Assinantes de marketing por email	47,500
Despesas de marketing digital	US $ 5,6 milhões

QUIDELORTO CORPORATION (QDEL) - Modelo de negócios: segmentos de clientes

Laboratórios de Diagnóstico Hospitalar

O Quidelorto atende a aproximadamente 5.000 laboratórios de diagnóstico hospitalar nos Estados Unidos. Esses laboratórios processam cerca de 2,3 bilhões de testes clínicos anualmente.

Tipo de laboratório	Penetração de mercado	Volume anual de teste
Grandes laboratórios hospitalares	65%	1,5 bilhão de testes
Laboratórios hospitalares de tamanho médio	28%	650 milhões de testes
Pequenos laboratórios hospitalares	7%	150 milhões de testes

Instituições de Pesquisa Clínica

O Quidelorto colabora com 750 instituições de pesquisa clínica em todo o mundo, apoiando aproximadamente 12.000 estudos de pesquisa ativos.

• Centros de pesquisa acadêmica: 450 instituições
• Organizações de pesquisa farmacêutica: 200 instituições
• Fundamentos de pesquisa privada: 100 instituições

Provedores de saúde

A empresa atende a mais de 25.000 prestadores de serviços de saúde em várias especialidades médicas.

Tipo de provedor	Número de provedores	Uso do teste de diagnóstico
Clínicas de atenção primária	15,000	40% do total de testes de diagnóstico
Centros médicos especializados	6,500	35% do total de testes de diagnóstico
Instalações de atendimento urgente	3,500	25% do total de testes de diagnóstico

Agências de saúde do governo

O Quidelorto fornece soluções de diagnóstico para 52 agências estaduais e federais de saúde, apoiando programas de monitoramento e intervenção em saúde pública.

• Colaboração do CDC: parceria direta
• Departamentos de Saúde do Estado: 48 contratos ativos
• Programas federais de saúde: 4 principais contratos

Clínicas médicas privadas e centros de teste

A empresa atende 8.500 clínicas médicas particulares e centros de testes independentes em todo o país.

Tipo de clínica	Número de clínicas	Volume anual de teste
Centros de diagnóstico privados	4,200	350 milhões de testes
Clínicas médicas especializadas	2,800	250 milhões de testes
Instalações de teste independentes	1,500	150 milhões de testes

Quidelortho Corporation (QDEL) - Modelo de negócios: estrutura de custos

Investimentos de pesquisa e desenvolvimento

A Quidelortho Corporation investiu US $ 292,7 milhões em despesas de pesquisa e desenvolvimento para o ano fiscal de 2023, representando 11,4% da receita total.

Ano	Investimento em P&D	Porcentagem de receita
2023	US $ 292,7 milhões	11.4%
2022	US $ 268,5 milhões	10.9%

Despesas de fabricação e produção

Os custos totais de fabricação para a Quidelortho em 2023 foram de US $ 456,3 milhões, com as principais instalações de produção localizadas em San Diego, Califórnia e Marlborough, Massachusetts.

• Custos diretos de mão -de -obra: US $ 87,2 milhões
• Despesas de matéria -prima: US $ 223,5 milhões
• Manufatura de sobrecarga: US $ 145,6 milhões

Despesas de vendas e marketing

A Quidelortho alocou US $ 312,6 milhões às atividades de vendas e marketing no ano fiscal de 2023.

Categoria de despesa	Quantia
Compensação do pessoal de vendas	US $ 142,3 milhões
Campanhas de marketing	US $ 87,5 milhões
Infraestrutura de suporte de vendas	US $ 82,8 milhões

Custos de conformidade e certificação regulatórios

As despesas de conformidade para Quidelortho totalizaram US $ 64,5 milhões em 2023, cobrindo os requisitos regulatórios da FDA, CE e Internacional.

• Custos de conformidade da FDA: US $ 28,3 milhões
• Despesas de certificação internacional: US $ 22,7 milhões
• Sistemas de gestão da qualidade: US $ 13,5 milhões

Distribuição global e logística

As despesas de distribuição e logística para Quidelortho atingiram US $ 176,4 milhões em 2023.

Componente de logística	Custo
Envio e transporte	US $ 89,2 milhões
Armazenamento	US $ 52,6 milhões
Distribuição internacional	US $ 34,6 milhões

QUIDELORTO CORPORATION (QDEL) - Modelo de negócios: fluxos de receita

Vendas de kits de teste de diagnóstico

O Quidelorto gerou US $ 2,49 bilhões em receita total para o ano fiscal de 2023. Os kits de teste de diagnóstico representam uma parcela significativa desse fluxo de receita.

Categoria de produto	Receita anual	Porcentagem da receita total
Kits de diagnóstico molecular	US $ 987 milhões	39.6%
Kits de teste de antígeno rápido	US $ 612 milhões	24.6%

Licenciamento de tecnologia de diagnóstico molecular

As receitas de licenciamento para tecnologias de diagnóstico molecular em 2023 totalizaram US $ 156 milhões.

• Licenciamento de tecnologia para instituições acadêmicas
• Acordos de licenciamento com centros de pesquisa farmacêutica
• Contratos internacionais de transferência de tecnologia

Contratos de serviço de teste clínico

Os contratos de serviço de teste clínico geraram US $ 423 milhões em 2023.

Tipo de contrato	Receita anual
Contratos de rede hospitalar	US $ 276 milhões
Parcerias de laboratório privado	US $ 147 milhões

CoVID-19 e vendas de testes de doenças infecciosas

As vendas de testes relacionadas à CoVID-19 em 2023 totalizaram US $ 512 milhões, representando um declínio dos anos de pico da pandemia.

Serviços de consultoria e suporte técnico

A receita de serviços de consultoria e suporte técnico atingiu US $ 98 milhões em 2023.

Categoria de serviço	Receita anual
Consultoria de Implementação Técnica	US $ 62 milhões
Serviços de treinamento e suporte	US $ 36 milhões

QuidelOrtho Corporation (QDEL) - Canvas Business Model: Value Propositions

You're looking at the core reasons why labs and clinics choose QuidelOrtho Corporation. It's about the breadth of their offering, the economics of their core systems, the speed of their critical tests, and the reliability of their support structure.

Comprehensive diagnostic portfolio from Point-of-Care to central lab testing is supported by a business structure that generated $700 million in total revenue for the third quarter of 2025. This portfolio spans multiple critical areas, with specific segment contributions in Q1 2025 including Point of Care generating $170.80 million and Labs revenue growing 5% as reported.

For central lab testing, the value proposition around the VITROS clinical chemistry systems centers on economics and performance. While a specific TCO (Total Cost of Ownership) percentage isn't public, the company is actively promoting accessibility through its Certified Analyzer Program, offering certified VITROS XT 7600 and 5600 Integrated Systems and the VITROS 3600 Immunodiagnostic System to smaller hospitals 'at a fraction of the cost.' The Labs business unit itself showed solid growth, with Q3 2025 revenue increasing 5% as reported.

The promise of rapid, accurate results is delivered through key platforms like Triage and Sofia. The Point of Care segment, which includes these rapid tests, brought in $170.80 million in revenue in the first quarter of 2025. Furthermore, QuidelOrtho Corporation announced FDA 510(k) Clearance for the VITROS Immunodiagnostic Products hs Troponin I Assay in late 2025, enhancing the cardiac marker offering.

Expertise in transfusion medicine and immunohematology is a major differentiator. QuidelOrtho Corporation maintained its position as the #1 global brand leader in Immunohematology as of early 2025. This expertise is critical in a market valued at $61.2 billion in 2024, projected to reach $88.8 billion by 2030. The Immunohematology revenue stream grew 4% as reported in Q2 2025.

High-touch customer service is quantified by industry recognition. In the 2025 IMV ServiceTrak Awards, QuidelOrtho Corporation achieved the #1 Overall Net Promoter Score (NPS) by Manufacturer, marking a 17-point increase in NPS, the largest gain in that category. The company has held the #1 ranking for Overall Customer Satisfaction since 2018. Service efficiency is also high, with 65% of all customer requests resolved remotely without needing onsite service.

Here's a quick look at the financial context supporting these value drivers:

Metric	Value/Rate (Latest Reported Period)	Period End Date
Full-Year 2025 Revenue Guidance Range	$2.68 - $2.74 billion	Q3 2025
Q3 2025 Adjusted EBITDA Margin	25%	September 28, 2025
Q3 2025 Labs Revenue Growth (As Reported)	5%	September 28, 2025
Immunohematology Revenue Growth (As Reported)	4%	June 29, 2025
NPS Increase (Largest Gain in Category)	17-point increase	2025 Awards

The commitment to operational excellence is evident in margin improvement, with the Adjusted EBITDA margin reaching 23% in Q1 2025 (a 450 basis point increase) and 25% in Q3 2025 (a 180 basis point improvement year-over-year). These improvements are driven by cost-saving initiatives, including achieving $100 million in annualized cost savings by mid-2025.

The value propositions are backed by specific service achievements:

• Ranked #1 Overall Manufacturer Performance in 2025 IMV ServiceTrak Awards.
• Ranked #1 Overall Service Engineer Performance in 2025 IMV ServiceTrak Awards.
• Ranked #1 Overall Training Performance in 2025 IMV ServiceTrak Awards.
• Offers certified VITROS systems for smaller facilities.
• Transfusion Medicine is the #1 global brand leader in Immunohematology.

Finance: draft 13-week cash view by Friday.

QuidelOrtho Corporation (QDEL) - Canvas Business Model: Customer Relationships

You're looking at how QuidelOrtho Corporation keeps its high-value diagnostic customers locked in, and honestly, it's all about making the switch to a competitor painful by embedding their products deep into your daily workflow. This isn't just about selling a machine; it's about selling uptime and efficiency, which is why a significant portion of their business is built on repeat purchases and ongoing support.

The core of the relationship for their central lab business-which made up 54% of total company revenue in Q1 2025-revolves around dedicated, long-term agreements. These contracts cover the big-ticket items, like the VITROS® Automation Solutions, ensuring you're locked into their ecosystem for reagents and service.

The financial proof of this sticky relationship is clear: over 90% of QuidelOrtho's revenue in Q4 2024 came from recurring sales of reagents, consumables, and services. That's the engine driving customer retention, so you know they prioritize keeping those instruments running and stocked.

Here's a quick look at how the recurring revenue streams and service contracts support the major lab segment:

Metric Category	Specific Data Point	Value/Amount
Recurring Revenue Base (Q4 2024)	Percentage of Total Revenue from Reagents/Consumables/Services	Over 90%
Segment Revenue Contribution (Q1 2025)	Labs Business Segment Revenue Share	54%
Total Company Revenue Context (Q3 2025)	Reported Total Revenue	$700 million
Underlying Business Momentum (Q3 2025)	Non-Respiratory Revenue Growth (Constant Currency)	6%

Automated, high-volume replenishment of reagents and consumables is the practical side of those long-term contracts. For instance, in Immunohematology, they offer a full line of reagent red blood cells designed to standardize and drive efficiency across your lab operations, whether you use manual, semi-manual, or automated testing systems. This ensures that once you commit to a platform like the Ortho Vision Swift Automated Immunohematology System, you're buying years of supply chain dependency.

When you need to optimize the actual process, you call in the specialists. QuidelOrtho offers specialized technical support and consulting services under the VALUMETRIX™ banner. These experts use globally recognized techniques like Lean Six Sigma thinking to evaluate and optimize your lab processes. They don't just talk theory; they show results. For example, in one STAT lab engagement, the VALUMETRIX™ Team's process refinement allowed for 10% growth while simultaneously cutting the mean chemistry turnaround time by 19%. Annual automated ValuChecks^SM are used to evaluate processes for continuous quality improvements, which is a great way to keep the consulting relationship active.

For your Point-of-Care (POC) platforms, like the Sofia® 2 analyzer, the relationship shifts toward self-service and digital support, though human teams are still involved. The Sofia® 2 analyzer includes on-board data management, capable of storing up to 1,000 tests (FIFO), and it can interface directly with EMR and LIS systems, which automates result transmission and cuts down on manual transcription errors. Furthermore, the integrated VIRENA™ wireless connectivity allows you to view results remotely and facilitates quality control monitoring across your entire network of Sofia 2 instruments.

The focus on service excellence is definitely paying off in customer perception. QuidelOrtho earned three awards in the 2025 IMV ServiceTrak™ Awards, including top rankings for Integrated Systems service. More importantly, their commitment to customer experience initiatives delivered a 17-point increase in Net Promoter Score (NPS), which is the largest gain in that category, showing higher customer loyalty and satisfaction.

For smaller, high-throughput settings like pharmacies using the Sofia 2 analyzer, they offer workflow partnerships. One such partnership enables pharmacies to onboard patients 80 percent faster than with a manual process, which is a concrete, time-saving metric that builds immediate trust. You can see the relationship strategy is tailored:

• Dedicated, long-term contracts for central lab automation.
• High-volume reagent sales driving over 90% of recurring revenue.
• Consulting services like VALUMETRIX™ achieving 19% turnaround time reductions.
• Digital self-service via VIRENA™ for POC platforms.
• Partnerships cutting pharmacy onboarding time by 80%.

Finance: draft 13-week cash view by Friday.

QuidelOrtho Corporation (QDEL) - Canvas Business Model: Channels

You're looking at how QuidelOrtho Corporation moves its diagnostic products-from high-sensitivity troponin assays to immunohematology systems-to the end-user, which is a mix of major hospitals, clinical labs, and international customers. Honestly, the channel strategy reflects the complexity of their portfolio, blending direct access for key accounts with broad distribution for scale.

Direct global sales force for major hospital and lab systems

The direct sales force is definitely the primary route for QuidelOrtho Corporation's core, high-value capital equipment and integrated systems, like the VITROS platform. This team handles the complex sales cycle required for major hospital networks and large reference laboratories. While we don't have a specific headcount for the direct sales team as of late 2025, we know the output of this channel is substantial, driving the performance of the core business units. For instance, the Labs business segment posted a revenue growth of 5% as reported in the third quarter of 2025, indicating strong traction through direct engagement with these large customers. This channel is critical for securing long-term reagent and consumable contracts following an initial instrument placement.

Third-party medical device distributors and wholesalers

For broader market penetration, especially in smaller clinical labs or for specific product lines like certain point-of-care offerings, QuidelOrtho Corporation relies on established third-party distributors and wholesalers. This leverages existing logistics networks you wouldn't want to build from scratch. The Immunohematology segment, which grew 4% as reported in Q3 2025, likely sees significant contribution from these indirect channels to reach transfusion medicine centers across various geographies. This approach helps manage the cost-to-serve for lower-volume accounts.

International commercial teams, especially in high-growth regions like China

QuidelOrtho Corporation maintains dedicated international commercial teams to manage regulatory compliance, local marketing, and direct sales efforts outside the U.S. The company noted a favorable impact from foreign currency translation of approximately 90 basis points on Q3 2025 revenue, showing that international sales are a meaningful part of the total $700 million quarterly revenue. While specific China revenue figures aren't broken out, the focus on global reach implies these teams are actively pushing the portfolio, including the recently FDA-cleared high-sensitivity troponin assay, into new markets to offset declines in other areas, like the winding down of the U.S. Donor Screening portfolio.

Online portals for ordering consumables and technical documentation

The digital channel is essential for recurring revenue and customer support efficiency. QuidelOrtho Corporation uses online portals for customers to manage orders for high-volume consumables and access critical technical documentation, like assay protocols or service manuals. This self-service model helps keep non-GAAP operating expenses down, which decreased by 7% in Q3 2025. It's the backbone for managing the installed base efficiently.

Here's a quick look at the revenue scale that these channels are moving as of the third quarter of 2025:

Revenue Segment (Q3 2025)	Reported Revenue (USD)	Year-over-Year Growth (Reported)
Total Reported Revenue	$700 million	-4%
Non-respiratory Revenue	$588 million	5%
Respiratory Revenue (Primarily COVID-19 decline)	$112 million	Decline driven by 63% drop in COVID-19 revenue
Labs Revenue (Within Non-respiratory)	Not explicitly stated	5%
Immunohematology Revenue (Within Non-respiratory)	Not explicitly stated	4%

The company's overall strategy is clearly weighted toward driving growth in the core Labs and Immunohematology segments through both direct and distributor channels, aiming for a full-year 2025 revenue guidance midpoint around $2.71 billion (based on Q1 estimates, narrowed to $2.68 billion-$2.74 billion in Q3). The success of the direct sales force is tied to securing placements that generate the recurring revenue from the 5% Labs growth.

You can find presentation materials and access replays for calls detailing these channel strategies on the Investor Relations page at https://ir.quidelortho.com.

Finance: draft 13-week cash view by Friday.

QuidelOrtho Corporation (QDEL) - Canvas Business Model: Customer Segments

You're looking at the core groups QuidelOrtho Corporation (QDEL) serves as of late 2025, which directly shapes how they structure their sales and R&D efforts. Honestly, the business is clearly segmented by the type of testing environment, moving away from pandemic-era reliance.

The company's Q3 2025 total reported revenue came in at $700 million, with non-respiratory revenue making up $588 million of that total, showing a 5% increase as reported for that non-COVID core business.

Central Clinical Laboratories and Reference Labs (high-volume testing)

This segment, which QuidelOrtho groups under its Labs business, is a key driver of the underlying growth. You see this reflected in their recent performance metrics.

• Labs business revenue grew 5% as reported in Q3 2025.
• The overall full-year 2025 revenue guidance is narrowed to a range of $2.68 billion to $2.74 billion.

Blood Banks and Transfusion Medicine Centers (global market leader)

QuidelOrtho Corporation positions itself as a global leader in diagnostics, with a strong focus here, evidenced by product announcements like the MTS DAT Card completion for their gel-based testing solutions. This segment is tied closely to the broader, high-value blood banking industry.

Here's a look at the market context for this customer base:

Metric	Value (2025 Estimate)	Source Context
Global Blood Banking Devices Market Value	$25.28 Billion	Estimated market value for 2025
North America Market Share (Devices)	42%	Estimated market share in 2025
Asia Pacific Market Share (Devices)	28%	Estimated market share in 2025
Immunohematology Revenue Growth (Q3 2025)	5%	Company segment growth rate

The company is actively managing its Donor Screening portfolio, projecting revenues between $40 million and $50 million for the full year 2025, while noting the wind-down of the U.S. Donor Screening business.

Point-of-Care settings: Physician offices, clinics, and Emergency Departments

For immediate testing needs, the Triage product line is the key indicator here. This area is showing strong momentum compared to other divisions.

• The Triage product line posted a 7% growth rate in Q3 2025.
• The Point of Care division, excluding COVID-19 business, was expected to see mid-single-digit growth for the full year 2025.

International healthcare systems (EMEA, Latin America, Japan)

Geographic diversity is important to QuidelOrtho Corporation's stability, especially as they manage the decline in U.S. COVID-19 and Donor Screening revenue. They report success in specific international areas.

You can see the geographic performance reflected in their recent results:

• The company registered robust revenues from EMEA, China and Other regions in Q3 2025.
• Growth in the Chinese market for 2025 is projected to be within the mid- to high-single-digit range.

Finance: draft 13-week cash view by Friday.

QuidelOrtho Corporation (QDEL) - Canvas Business Model: Cost Structure

You're looking at the expense side of the QuidelOrtho Corporation (QDEL) model, which is heavily influenced by manufacturing complexity and ongoing integration efforts. Here's a breakdown of the key cost drivers based on late 2025 figures.

The cost structure reflects the ongoing integration following the merger and the inherent expense in producing diagnostic tools. For instance, the third quarter of 2025 saw significant one-time charges related to these activities.

Integration and restructuring charges hit the books hard in Q3 2025, totaling $40 million. This charge included approximately $11 million tied to stopping the development of the Savanna platform and about $28 million for ERP system integration costs. Year-to-date through Q3 2025, the cumulative restructuring, integration, and other charges reached $234.6 million.

Manufacturing and product costs are a major component, suggested by the reported adjusted gross profit margin. For the third quarter of 2025, the adjusted gross profit margin stood at 48.7%. This margin reflects the cost of goods sold (COGS) relative to revenue, which is naturally high given the complex reagent and instrument manufacturing involved in their diagnostic offerings.

Investment in the future pipeline is another significant outflow. Research and development (R&D) is a necessary expense for platform integration and new product launches. The company reported GAAP R&D expenses of $41.5 million for the third quarter of 2025.

The operational overhead for running a global commercial presence is substantial. Sales, General, and Administrative (SG&A) expenses, combined with R&D, make up the non-GAAP operating expenses. For Q3 2025, the combined non-GAAP operating expenses (SG&A and R&D) were $217 million, representing a 7% decrease year-over-year due to cost savings actions. Year-to-date through Q3 2025, non-GAAP SG&A alone was $525.8 million.

Finally, the cost of capital is a growing factor. Following a recent refinancing, QuidelOrtho Corporation projects its full-year 2025 interest expense on debt to be $177 million. This projection was an increase of $17 million from prior expectations, attributed to the August refinancing raising the weighted average rate by about 100 basis points and higher amortization of financing fees. The net interest expense recorded in Q3 2025 was $46.1 million.

Here's a summary of the key cost components for the third quarter of 2025 and full-year 2025 projections:

Cost Component	Q3 2025 Amount (Millions USD)	Year-to-Date Q3 2025 Amount (Millions USD)	FY 2025 Projection (Millions USD)
Restructuring, Integration, and Other Charges	$40.0	$234.6	N/A
GAAP Selling, Marketing and Administrative (SG&A)	N/A	$551.9	N/A
Non-GAAP SG&A + R&D (Total Operating Expenses)	$217.0	N/A	N/A
GAAP Research and Development (R&D)	$41.5	$140.4	N/A
Interest Expense, Net	$46.1	$126.6	$177.0

The operational cost management is evident in the reduction of combined non-GAAP operating expenses. You can see the impact of cost savings initiatives in these figures:

• Non-GAAP operating expenses (SG&A + R&D) decreased by $16 million or 7% in Q3 2025 versus prior year.
• Achieved $100 million annualized cost-savings initiatives as of Q2 2025 guidance.
• Targeting an additional $30-$50 million of cost-savings in the remainder of 2025.

The high fixed cost base is also reflected in the GAAP results, which included a non-cash goodwill impairment charge of $701 million in Q3 2025. This charge significantly impacted the GAAP operating margin, which was (101)% for the quarter.

Finance: draft 13-week cash view by Friday.

QuidelOrtho Corporation (QDEL) - Canvas Business Model: Revenue Streams

You're looking at the core engine of QuidelOrtho Corporation's revenue generation as of late 2025. Honestly, the story here is about the shift from pandemic-driven peaks to the more sustainable, albeit lower, base business. The company's financial guidance frames this transition quite clearly.

Full-Year 2025 Revenue Expectations

Management has narrowed its full-year 2025 total reported revenue guidance to a range of $2.68 billion to $2.74 billion. This guidance reflects confidence in the core operations even as legacy revenue streams normalize. For context, the trailing twelve months revenue as of the end of Q3 2025 was reported at $2.71 Billion USD.

The revenue streams are fundamentally built around the consumables that keep the installed base of diagnostic equipment running. You'll see this reflected in the high percentage attributed to recurring sales.

• Recurring revenue constituted 97% of QuidelOrtho Corporation's total revenue for the third quarter of 2025.
• Non-respiratory revenue for Q3 2025 was $588 million.
• Non-respiratory revenue, excluding the U.S. Donor Screening exit, grew 6% in constant currency for Q3 2025.

The growth drivers within this recurring base are what management is leaning on to offset the expected decline in COVID-19 testing. For instance, in Q3 2025, the Labs business revenue grew 5% as reported, and the Triage product line posted 7% growth. Also, the Immunohematology segment saw growth of 5% in that same quarter.

Here's a quick math look at how the major components are expected to stack up for the full year 2025:

Revenue Component	Projected FY2025 Amount/Range
Full-Year Total Reported Revenue Guidance	$2.68 billion to $2.74 billion
COVID-19 Testing Revenue Projection	$70 million to $100 million

Instrument Sales and Service Contracts

While the bulk of revenue is recurring consumables, the initial placement of instruments-like the VITROS platform-is key to securing that future consumable stream. Instrument sales and leases are the initial transaction that locks in the long-term consumable revenue. Service and maintenance contracts for these installed diagnostic systems are defintely bundled into the recurring revenue stream, supporting the 97% figure reported for Q3 2025. The company is also focused on new assay clearances, such as the VITROS high-sensitivity troponin assay, which is designed to drive future utilization.

The COVID-19 Revenue Normalization

The most significant change in the revenue profile is the expected drop in COVID-19 testing revenue. Management now projects COVID-19 revenue for the full year 2025 to be in the range of $70 million to $100 million. This compares to the prior year's figures, where Q3 2025 COVID-19 revenue was down 63% year-over-year, contributing to the overall revenue decline in that quarter. The company is clearly moving toward an endemic-level expectation for this revenue line.